Abstract Details

Title Fetal Outcomes in Women with Epilepsy on Anti-Epileptic Drugs

Topic Epilepsy

Presentation(s) P04 - (-)

Poster/Presentation
Number 205

Objective

Background BACKGROUND: Estimates of the US population indicate that approximately 5 births per thousand will be to women with epilepsy. Complications and adverse perinatal outcomes have been reported in women with epilepsy.

Design/Methods DESIGN/METHODS: We performed a retrospective chart review of pregnant women with epilepsy on AED's who had delivered at Hahnemann University hospital in the past 10 years and compared their birth data to infants born to healthy women. Women with other medical problems, other medication use, smoking and alcohol use, non-compliance with AED's, positive urine drug screen, use of multiple AED's, changes in AED regimen, uncontrolled seizures, and twin pregnancy were excluded. The women on AED's were further subdivided based on the AED being taken and birth data was compared.

Results RESULTS: A total of 50 women were compared to 50 healthy controls. The average weight in the control group was 3337 grams versus 3089 grams in the AED's group (P= 0.0125). The average Apgar score at one minute in the control group was 8.8 and in the AED group was 7.9 (P= 0.0001). There was no statistical difference when Apgar scores at 5 minutes, head circumference, birth length, and weeks at delivery were analyzed. Patients on Levetiracetam (n=10) had the earliest average delivery at 37.2 weeks and the lowest birth weight on average at 2837 grams. There were no significant differences among the different AED groups with head circumference, birth length, and apgar scores. There were no congenital malformations or birth complications.

Conclusions CONCLUSIONS: Women on AED's had lower Apgar scores at 1 minute and lower birth weights. Women taking Levetiracetam had lower birth weights and delivered earlier.

Authors/Disclosures
Tooba Fayyaz, DO, FAAN PRESENTER	No disclosure on file
Jyoti Pillai, MD, MBBS, MRCP, FAAN, FAAN (Tower Health/Drexel University College of Medicine)	Dr. Pillai has a non-compensated relationship as a President with Pennsylvania Neurological Association that is relevant to AAN interests or activities.
Kerstin Hellwig (St. Josef Hospital Bochum)	Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from BMS .

��ɫ��

��ɫ��